Ani Pharmaceuticals (ANIP) Common Equity (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Common Equity data on file, last reported at $562.3 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 761.5% year-over-year to $562.3 million; the trailing twelve-month figure through Mar 2026 stood at $562.3 million (up 761.5% YoY), and the FY2025 full-year result was $540.7 million, up 2669.98% from the prior year.
• Common Equity advanced to $562.3 million in Q1 2026, from $540.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $562.3 million in Q1 2026 to a low of -$85.0 million in Q1 2025.
• A 5-year average of $165.1 million and a median of $2000.0 in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity sank 758.55% in 2023 and surged 52362700.0% in 2024, its largest moves.
• Tracing ANIP's Common Equity over 5 years: stood at $12.2 million in 2022, then slumped by 758.55% to -$80.1 million in 2023, then soared by 73.74% to -$21.0 million in 2024, then jumped by 2669.98% to $540.7 million in 2025, then grew by 3.99% to $562.3 million in 2026.
• Business Quant data shows ANIP's Common Equity at $562.3 million in Q1 2026, $540.7 million in Q4 2025, and $505.8 million in Q3 2025.